Tweet
Is it unacceptable to remove chimeras, shorter than expected reads, and low q-score reads prior to doing a rarefaction analysis? I'm working with 454 16S data and it just makes sense to remove this kind of data from each library prior to alignment and clustering. I've been questioned on my method that told that rarefaction analysis should be calculated on raw data. Thoughts?
-
Last edited by lisa.brown; 02-11-2014, 07:29 AM. -
Would you have used those reads anyway for downstream analyses? If not, then I would find it difficult to argue against removing them. -
Great! That's my reasoning as well, the removed reads WOULDN'T be used for downstream analysis so why produce rarefaction data that isn't comparable to downstream hierarchy data?Comment
-
Kheloyar – Everything You Need to Know About Kheloyaar Login and Kheoyar Id
If you are looking for an online gaming platform that offers a user-friendly experience, Kheloyar has become a name that many users search for. Whether you're interested in creating a new account, accessing your dashboard through Kheloyaar Login, or learning how to obtain a Kheoyar Id, understanding the platform's features and account process is essential.
This guide explains everything you need to know about...Today, 01:13 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment